UK animal-genetics company breeding and selling superior pig (PIC) and cattle (ABS) breeding stock.
UK animal-genetics company breeding and selling superior pig (PIC) and cattle (ABS) breeding stock.
PIC is paid in part through royalties on the pigs its customers produce from its breeding stock, which ties income to herd size and pork production, while ABS sells bull semen to dairy and beef farmers. A gene-edited pig resistant to the PRRS virus, a major swine disease, is in development and needs approvals in export markets.
In one line: A UK genetics-focused livestock supplier.
Moat: wide (IP / patents, scale, installed base). Decades of proprietary genetic-selection data give a hard-to-replicate breeding lead.
Headquarters: Basingstoke, UK · Founded: 1996 · Employees: 3,054
Size Genus (GNS.L) is a United Kingdom Consumer Staples company (Agricultural Commodities/Milling) with a market value of $1.81B, the 166th largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £2,156 on 18 Nov 2026.
Performance Over six months the shares fell 13.0%, against +1.3% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue fell 2.2% over the last twelve months (peer median +4.3%); the operating margin is 13.3% (peer median 7.4%).
Valuation It trades at 21.2× forward earnings against a peer median of 15.8× (5th most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.3 points below its cost of capital (12.2% WACC).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | £658M | £658M | £673M | £669M | £690M |
| Revenue growth | — | -2% | +1% | -3% | — |
| Gross profit | £617M | £223M | £207M | £192M | £247M |
| EBITDA | £128M | £123M | £114M | £103M | £104M |
| Net income | £285M | £285M | £19.3M | £7.90M | £33.3M |
| Free cash flow | £78.0M | £78.0M | £59.9M | £19.7M | £27.1M |
| Capital expenditure | £18.1M | £18.1M | £18.6M | £24.7M | £35.2M |
| Total debt | n/a | £108M | £266M | £291M | £232M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GNS.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.1% | -4.3% | 8th highest of 21 |
| 6-month return | -13.0% | +1.3% | 10th lowest of 20 |
| Distance from 52-week high | -33.0% | -26.9% | 9th lowest of 21 |
| Revenue growth (TTM) | -2.2% | +4.3% | 6th lowest of 21 |
| Operating margin | 13.3% | 7.4% | 7th highest of 21 |
| Forward P/E | 21.2× | 15.8× | 5th most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 16.1% | 1.9% | 2nd most demanding of 13 |
| Growth delivered (Del g) | +2.8% | +12.0% | 4th lowest of 13 |
| Hurdle (Req g minus delivered) | +13.3 pp | -5.9 pp | 2nd most demanding of 13 |
| ROIC minus cost of capital | -4.3 pp | -1.6 pp | 7th lowest of 21 |
| EV / EBITDA | 11.3× | 11.1× | 6th cheapest of 11 |
| Net debt / EBITDA | 0.5× | 1.7× | 3rd least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Genus GNS.L | United Kingdom | $1.81B | -13% | -2% | 13% | 21.2× | 16.1% | +2.8% |
| Beijing Dbn Technology 002385.SZ | China | $1.78B | -22% | -1% | -6% | n/a | n/a | n/a |
| BioMar Group A/S BIOMAR.CO | Denmark | $1.85B | -31% | 0% | 6% | 13.6× | -1.2% | -0.5% |
| Uie UIE.CO | Denmark | $1.71B | +8% | +11% | 40% | n/a | -15.2% | +13.1% |
| Trulieve Cannabis TRLV | United States | $1.93B | +25% | -9% | 15% | 28.5× | 11.2% | +17.8% |
| Tecon Biology 002100.SZ | China | $1.69B | +14% | -8% | -5% | n/a | n/a | n/a |
| Guangxi Yuegui Guangye 000833.SZ | China | $1.96B | -46% | +67% | 30% | 8.6× | 0.4% | -0.9% |
| Yuan Longping High-Tech Agriculture 000998.SZ | China | $1.65B | -14% | -5% | 5% | 43.5× | n/a | n/a |
| Jiangsu Provincial Agricultural Reclamation & Dev 601952.SS | China | $1.63B | -13% | -5% | 4% | 19.0× | -2.9% | +3.2% |
| Bumitama Agri P8Z.SI | Singapore | $1.61B | -28% | +9% | 25% | 8.9× | -16.8% | +12.9% |
| Curaleaf CURA.TO | Canada | $2.10B | -17% | +5% | 1% | n/a | n/a | n/a |
| LT Foods LTFOODS.NS | India | $1.56B | +2% | +24% | 8% | 12.8× | 25.8% | +18.2% |
| Shenzhen Agricultural Products 000061.SZ | China | $1.52B | -22% | -22% | 12% | 24.4× | 3.5% | +15.6% |
| China Modern Dairy 1117.HK | Hong Kong | $1.50B | +29% | +5% | -15% | 13.7× | n/a | n/a |
| Lien Hwa Industrial 1229.TW | Taiwan | $2.20B | +2% | +1% | 19% | n/a | 12.0% | +7.3% |
| Liuliumei 6658.HK | Hong Kong | $1.46B | n/a | +6% | 12% | n/a | n/a | n/a |
| B.F BFG.MI | Italy | $2.26B | +59% | +30% | -2% | 85.0× | n/a | n/a |
| Shandong Yisheng Livestock & Poultry Breeding 002458.SZ | China | $1.44B | -25% | +15% | 17% | 17.2× | 5.4% | +11.1% |
| Balrampur Chini Mills BALRAMCHIN.NS | India | $1.44B | +16% | +11% | 9% | 18.7× | n/a | n/a |
| Kernel KER.WA | Poland | $1.43B | +1% | -1% | 5% | 5.3× | 8.1% | -5.4% |
| Fuji Oil 2607.T | Japan | $2.30B | +24% | +4% | 5% | 14.4× | 0.4% | +16.2% |